Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving leading biopharmaceutical companies globally:

Federal Trade Commission
Queensland Health
US Department of Justice
Citi
Boehringer Ingelheim
US Army
UBS
McKesson
Cerilliant
QuintilesIMS

Generated: October 20, 2017

DrugPatentWatch Database Preview

ELI LILLY AND CO Company Profile

« Back to Dashboard

What is the competitive landscape for ELI LILLY AND CO, and what generic alternatives to ELI LILLY AND CO drugs are available?

ELI LILLY AND CO has six approved drugs.

There are eighteen US patents protecting ELI LILLY AND CO drugs.

There are two hundred and twenty-nine patent family members on ELI LILLY AND CO drugs in forty-three countries and fifty-six supplementary protection certificates in twelve countries.

Summary for Applicant: ELI LILLY AND CO

International Patents:229
US Patents:18
Tradenames:7
Ingredients:6
NDAs:6
Drug Master File Entries: (click here to view)37
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Eli Lilly And Co
EFFIENT
prasugrel hydrochloride
TABLET;ORAL022307-001Jul 10, 2009ABRXYesNo► Subscribe► Subscribe► Subscribe
Eli Lilly And Co
BASAGLAR
insulin glargine
SOLUTION;SUBCUTANEOUS205692-001Dec 16, 2015RXNoNo► Subscribe► Subscribe► Subscribe
Eli Lilly And Co
EFFIENT
prasugrel hydrochloride
TABLET;ORAL022307-001Jul 10, 2009ABRXYesNo► Subscribe► SubscribeY► Subscribe
Eli Lilly And Co
AXIRON
testosterone
SOLUTION, METERED;TRANSDERMAL022504-001Nov 23, 2010DISCNYesNo► Subscribe► Subscribe ► Subscribe
Eli Lilly And Co
AXIRON
testosterone
SOLUTION, METERED;TRANSDERMAL022504-001Nov 23, 2010DISCNYesNo► Subscribe► Subscribe ► Subscribe
Eli Lilly And Co
HUMALOG KWIKPEN
insulin lispro recombinant
SOLUTION;SUBCUTANEOUS205747-001May 26, 2015RXYesYes► Subscribe► SubscribeY ► Subscribe
Eli Lilly And Co
AXIRON
testosterone
SOLUTION, METERED;TRANSDERMAL022504-001Nov 23, 2010DISCNYesNo► Subscribe► Subscribe ► Subscribe
Eli Lilly And Co
AXIRON
testosterone
SOLUTION, METERED;TRANSDERMAL022504-001Nov 23, 2010DISCNYesNo► Subscribe► SubscribeY ► Subscribe
Eli Lilly And Co
AXIRON
testosterone
SOLUTION, METERED;TRANSDERMAL022504-001Nov 23, 2010DISCNYesNo► Subscribe► SubscribeY ► Subscribe
Eli Lilly And Co
EFFIENT
prasugrel hydrochloride
TABLET;ORAL022307-002Jul 10, 2009ABRXYesYes► Subscribe► SubscribeY► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Expired Patents for Eli Lilly And Co

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Eli Lilly And Co
PROZAC
fluoxetine hydrochloride
CAPSULE;ORAL018936-006Dec 23, 1992► Subscribe► Subscribe
Eli Lilly And Co
PROZAC
fluoxetine hydrochloride
CAPSULE;ORAL018936-001Dec 29, 1987► Subscribe► Subscribe
Eli Lilly And Co
SARAFEM
fluoxetine hydrochloride
CAPSULE;ORAL018936-007Jul 6, 2000► Subscribe► Subscribe
Eli Lilly And Co
AXIRON
testosterone
SOLUTION, METERED;TRANSDERMAL022504-001Nov 23, 2010► Subscribe► Subscribe
Eli Lilly And Co
PROZAC
fluoxetine hydrochloride
CAPSULE;ORAL018936-001Dec 29, 1987► Subscribe► Subscribe
Eli Lilly And Co
PROZAC
fluoxetine hydrochloride
CAPSULE;ORAL018936-001Dec 29, 1987► Subscribe► Subscribe
Eli Lilly And Co
PROZAC
fluoxetine hydrochloride
CAPSULE;ORAL018936-001Dec 29, 1987► Subscribe► Subscribe
Eli Lilly And Co
PROZAC
fluoxetine hydrochloride
CAPSULE;ORAL018936-001Dec 29, 1987► Subscribe► Subscribe
Eli Lilly And Co
PROZAC
fluoxetine hydrochloride
CAPSULE;ORAL018936-001Dec 29, 1987► Subscribe► Subscribe
Eli Lilly And Co
SARAFEM
fluoxetine hydrochloride
CAPSULE;ORAL018936-008Jul 6, 2000► Subscribe► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Paragraph IV activity for ELI LILLY AND CO drugs

Drugname Dosage Strength Tradename Submissiondate
prasugrel hydrochloride
Tablets5 mg and 10 mg
EFFIENT
7/10/2013
testosterone
Topical Solution30 mg/1.5 mL
AXIRON
1/29/2013

Non-Orange Book Patents for Eli Lilly And Co

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,427,275Medication dispensing apparatus with triple screw threads for mechanical advantage► Subscribe
6,929,801 Transdermal delivery of antiparkinson agents► Subscribe
5,436,242 Tetrahydrothienopyridine derivatives, furo and pyrrolo analogs thereof for inhibiting blood platelet aggregation► Subscribe
8,357,393Transdermal delivery rate control using amorphous pharmaceutical compositions► Subscribe
7,094,422Topical delivery of antifungal agents► Subscribe
7,387,789Transdermal delivery of non-steroidal anti-inflammatory drugs► Subscribe
6,916,486 Transdermal delivery of analgesics► Subscribe
8,177,449Spreading implement► Subscribe
6,916,487 Transdermal delivery of antiemetics► Subscribe
6,964,777 Transdermal delivery of antianxiety agents► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Because of the complexity of determining patent expiration dates it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

International Patent Family for Eli Lilly And Co Drugs

Country Document Number Estimated Expiration
TaiwanI226829► Subscribe
European Patent Office1769785► Subscribe
Denmark1350511► Subscribe
Denmark1674068► Subscribe
World Intellectual Property Organization (WIPO)2008083423► Subscribe
Eurasian Patent Organization019214► Subscribe
European Patent Office1534235► Subscribe
South Africa200006815► Subscribe
Hungary0400644► Subscribe
Slovakia287972► Subscribe
This preview shows a limited data set
Subscribe for full access, or try a Trial

The estimated expiration dates shown above are derived by simply adding 20 years to the priority date.
Due to the complexity of determining patent expirations even in a single country, compounded by the diversity of global patent laws, it is advisable to have patent counsel verify freedom to operate.

Export unavailable in trial.
Subscribe for complete access.

Supplementary Protection Certificates for Eli Lilly And Co Drugs

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
971Luxembourg► Subscribe91971, EXPIRES: 20220219
C0085France► SubscribePRODUCT NAME: LIRAGLUTIDE ET INSULINE DEGLUDEC; REGISTRATION NO/DATE: EU/1/14/947 20140918
90036-0Sweden► SubscribePRODUCT NAME: KOMBINATION AV INSULIN DEGLUDEK OCH INSULIN ASPART; REG. NO/DATE: EU/1/12/806/001 20130121
2014000114Germany► SubscribePRODUCT NAME: KOMBINATION VON INSULIN DEGLUDEC UND LIRAGLUTIDE; REGISTRATION NO/DATE: EU/1/14/947 20140918
00521Netherlands► SubscribePRODUCT NAME: FENTANYL; REG NO/DATE: EU/2/11/127/001 20111006
C0009France► SubscribePRODUCT NAME: INSULINE GLULISINE; REGISTRATION NO/DATE IN FRANCE: EU/1/04/258/001 DU 20040927; REGISTRATION NO/DATE AT EEC: EU/1/04/285/001 DU 20040927
973Luxembourg► Subscribe91973, EXPIRES: 20220219
213Luxembourg► SubscribePRODUCT NAME: INSULINE DEGLUDEC SOUS TOUTES LES FORMES PROTEGEES PAR LE BREVET DE BASE
2209800/01Switzerland► SubscribePRODUCT NAME: INSULIN DEGLUDEC + LIRAGLUTIDE; REGISTRATION NO/DATE: SWISSMEDIC 65041 12.09.2014
C/GB96/036United Kingdom► SubscribePRODUCT NAME: INSULIN LISPRO, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY-ACCEPTABLE SALT; REGISTERED: CH 53290 19951123; CH 53553 19951123; UK EU/1/96/007/001 19960430; UK EU/1/96/007/002 19960430; UK EU/1/96/007/003 19960430
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Similar Applicant Names

Individual applicants are sometimes listed under multiple names.
Here is a list of applicants with similar names.

« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving leading biopharmaceutical companies globally:

McKesson
Deloitte
Dow
Cerilliant
QuintilesIMS
Medtronic
Fuji
Chinese Patent Office
Harvard Business School
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted
Privacy and Cookies
Terms & Conditions

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot